Oxaliplatin

In a video interview with Healio, Cecilia Monge, MD, MPH, FACP, from the NCI Center for Cancer Research at NIH, talked about the NAPOLI 3 trial data presented at ASCO Gastrointestinal Cancers Symposium.

A recent study showed that neoadjuvant modified FOLFIRINOX alone vs. with hypofractionated radiotherapy extended survival in patients with borderline resectable pancreatic cancer.

In the treatment of locally advanced gastric cancer, apatinib combined with S-1 plus oxaliplatin was a safe and effective neoadjuvant treatment, according to a nonrandomized controlled study.

Short-term radiotherapy combined with chemotherapy may be a suitable alternative to long-term radiotherapy for patients with advanced rectal cancer, according to data from a multicenter, randomized, phase 3 trial presented at ASCO21.

For years, standard treatment for patients with stage III colon cancer has been adjuvant chemotherapy for 6 months following resection.